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Introduction
Since the landmark randomized trials in 2015 
resulting in the HERMES meta-analysis in 2016 
endovascular thrombectomy (EVT) has become 
the standard of care for large vessel occlusion 
(LVO) strokes in the anterior circulation within a 
time window of 6 h after onset of symptoms.1 
Whereas these trials demonstrated that EVT is a 
very powerful treatment with a number needed to 
treat of ~2.5, they excluded a large proportion of 
patients potentially eligible for EVT due to very 
strict inclusion criteria.2–5 In this context, redefin-
ing the criteria to evaluate and select patients with 
LVO for endovascular treatment has become 
more and more important, because 3–22% of 
patients with ischemic stroke are potentially eligi-
ble for this treatment,6–8 and this percentage may 
be even greater when including more distal occlu-
sions and occlusions in the posterior circulation.
In this review, we therefore give an update on 
recent literature of borderline indications in patients 
who were excluded or underrepresented in the 
HERMES meta-analysis. Specifically, we present 
advances concerning patients in the late time 
window beyond 6 h of symptom onset, of patients 
with far progressed signs of brain infarction, of 
patients with vessel occlusions in the posterior cir-
culation and very old patients (nonagenarians) or 
patients with a pre-existing disability. Further, we 
discuss the evidence on “bridging” thrombolysis in 
patients who undergo EVT, of patients with more 
distal vessel occlusions, milder strokes, tandem 
occlusion and of pediatric patients in whom etiolo-
gies are much different. Finally, we compare the 
recommendations of the most recent guidelines 
and give our own recommendation for clinical 
practice (summarized in Table 1).
Borderline indications for EVT
Time from symptom onset
Less than 5% of 1287 patients randomly assigned 
in five large randomized trials were treated beyond 
6 h of symptom onset, so that evidence from these 
trials was scarce.1–3,5,9 In 2018, the DAWN and 
DEFUSE-3 randomized trials provided robust 
evidence that outcomes for disability at 90 days 
were better with thrombectomy plus standard 
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care than with standard care alone in patients in 
the extended time window of up to 24 h after 
onset of symptoms.10,11 A key selection criterion 
for both trials was advanced imaging used to 
define a mismatch between the infarct core lesion 
and the tissue at risk (DEFUSE-3)10 or between 
core lesion and the clinical deficit (DAWN).11 
However, both trials had restrictive selection cri-
teria meaning that around 70% of patients with 
anterior circulation LVO assessed between 6 and 
24 h after onset of symptoms do not comply with 
the DAWN and/or DEFUSE-3 criteria.12 There is 
evidence that EVT in these patients results in a 
positive treatment effect, even comparable to the 
effect of DAWN and DEFUSE-3 eligible 
patients12 suggesting that further evidence for 
patients presenting beyond 6 h but not fulfilling 
DAWN and DEFUSE-3 inclusion criteria is war-
ranted. This is currently being addressed by the 
ongoing MR CLEAN-LATE (ISRCTN19922220) 
and RESILIENT Extend (NCT02216643) trials 
investigating whether a simpler imaging paradigm 
without computed tomographic perfusion (CTP) 
or magnetic resonance imaging (MRI) could be 
used for EVT patient selection beyond 6 h. In this 
context, we currently recommend to perform 
EVT in the late window depending on the degree 
of potentially salvageable penumbra determined 
by advanced imaging. This may be the case even 
later than 24 h after onset of symptoms.13,14
Extent of infarction
In four of the five 2015 randomized trials, patients 
with early ischemic signs seen as an Alberta Stroke 
Program Early Computed Tomography Scan 
score (ASPECTS) below 6 or 7 were excluded. 
Only the MR CLEAN trial allowed for a small 
number of patients with low ASPECTS. In this 
trial, there was no treatment effect of EVT in 28 
patients with ASPECTS 0–4, while in 92 patients 
with ASPECTS 5–7 a trend for a treatment ben-
efit of EVT was observed.3 A 2018 HERMES 
meta-analysis showed that EVT led to better clini-
cal outcomes at 90 days in patients with ASPECTS 
<6 [odds ratio (OR) = 1.58 for ASPECTS 5–7 
and OR = 2.15 for ASPECTS 0–4] supporting the 
value of thrombectomy in some patients with large 
infarcts at baseline.15 Likewise, a registry study 
including 218 patients with a diffusion-weighted 
imaging (DWI) ASPECTS ⩽6 found an increased 
rate of favorable outcomes and a decreased rate of 
mortality in patients with successful reperfusion 
compared to non-reperfused patients.16 However, 
differences in the rate of favorable outcome were 
not significantly different and mortality increased 
in patients with a DWI ASPECTS <5. ASPECTS 
scores determined by DWI will likely differ from 
those ascertained using computed tomography 
(CT) due to different sensitivities for early ischemic 
changes.17 Nevertheless, a multicentre study with 
CT-based ASPECTS selection found that suc-
cessful recanalization in patients with low initial 
ASPECTS of ⩽5 resulted in a significant reduc-
tion of edema and was associated with decreased 
prevalence of malignant infarctions and improve-
ment in clinical outcome.18 This is in line with a 
recent meta-analysis suggesting that patients with 
ASPECTS 0–6 may benefit from EVT. In this 
analysis successful reperfusion increased the prob-
ability functional independence at 3 months with-
out increasing the risk of symptomatic intracerebral 
hemorrhage. The authors found that even in 
ASPECTS 4 patients, one in four would be inde-
pendent, whereas only 14% of patients with 
ASPECTS 0–3 regained a good functional out-
come.19 In conclusion, there is to date insufficient 
high-quality evidence to suggest that EVT is both 
safe and effective in patients with low ASPECTS 
scores. This was also acknowledged by experts of 
the European Stroke Organisation, the European 
Society for Minimally Invasive Neurological 
Therapy (ESMINT), and the European Society 
of Neuroradiology in a consensus statement on 
thrombectomy,20 leading to the initiation of sev-
eral randomized controlled trials such as 
TENSION21 and RESCUE-Japan LIMIT 
(ClinicalTrials.gov: NCT03702413). However, 
we conclude that patients with ASPECTS 4–6 
should be treated with EVT and even patients 
with ASPECTS lower than 3 might benefit in 
selected cases.
Vertebrobasilar artery occlusions
Meta-analyses of retrospective studies found high 
rates of recanalization and functional independ-
ence and a good safety profile for patients with 
basilar artery occlusion.22,23 However, a recent 
randomized trial investigating the safety and effi-
cacy of EVT for vertebrobasilar artery occlusions 
found no significant difference in favorable out-
comes of patients receiving endovascular therapy 
compared with those receiving standard medical 
therapy alone.24 However, the authors acknowl-
edged the use of outdated thrombectomy devices 
for some patients and the fact that loss of equipoise 
over the course of the trial25,26 resulted in poor 
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adherence to the assigned (conservative) treat-
ment, a fact that led to a reduced sample size and 
early termination of the study.24 No definite con-
clusion on EVT in basilar artery occlusion should 
therefore be drawn from this trial, especially when 
treating patients with small infarct cores. In con-
trast, we recommend to perform EVT in patients 
with vertebrobasilar artery occlusions.
Age and pre-existing disability
Significant pre-existing disability may preclude 
favorable clinical outcomes despite successful 
EVT and most clinical trials excluded chronically 
disabled patients with the exception of the MR 
CLEAN trial, leading to 21 patients with modified 
Rankin Scale (mRS)>1 being included in the 
analysis.3 However, no separate analysis has been 
performed for these patients so that no rand-
omized data exist to date for the potential benefit 
of thrombectomy in patients with mRS scores >1.
Importantly, there is no concerning safety signal in 
this population. For patients aged >80 years, a 
HERMES collaboration analysis showed signifi-
cant benefit of thrombectomy.1 Even for nonage-
narians multiple studies evaluating thrombectomy 
have shown promising results.27,28 In a recent anal-
ysis including 124 nonagenarians from the ETIS 
Registry, patients with successful reperfusion had 
lower 90-day mRS compared to non-recanalized 
patients. Moreover, patients with successful reper-
fusion after one pass had reduced 90-day mortality 
and increased odds of good outcome (mRS score 
⩽3).29 The authors concluded that in case of first-
pass failure, terminating the intervention might be 
an advisable procedural strategy for this fragile 
subpopulation. This interesting finding empha-
sizes the high impact of successful reperfusion on 
favorable outcomes.29 In 37% (14 of 38) of 
patients, good outcome was achieved with >1 pass 
leading to successful reperfusion or even without 
successful reperfusion. Even more interestingly, in 
54% (29 of 53) of all first-pass effect cases, 90-day 
outcome was neither favorable nor good.29 
Therefore, terminating the procedure after failed 
first-pass reperfusion of thrombolysis in cerebral 
infarction (TICI) ⩾2b might not be justified. 
Furthermore, as we become even faster in inter-
ventional stroke treatment with new workflow par-
adigms like the one-stop management, it might be 
possible to perform multiple thrombectomy 
maneuvers in the same door-to-reperfusion time as 
for one try in the past.30,31 The safety analysis 
showed low overall rates of symptomatic cerebral 
hemorrhage of 4% and no significant difference in 
complications between successful and unsuccess-
ful reperfusion groups, justifying further thrombec-
tomy attempts.29 Overall, these findings underline 
that age itself should not be a criterion to exclude 
patients from EVT but future studies are war-
ranted to elucidate why very elderly patients with 
predictors for good outcome still experience poor 
long-term outcomes.
We conclude that age and pre-existing deficits 
should not lead to exclusion of these patients 
from EVT.
Thrombectomy and intravenous thrombolysis
In the 2015 randomized EVT trials, patients eligi-
ble for intravenous (IV) thrombolysis with recom-
binant tissue plasminogen activator (rtPA; 
alteplase) received both treatments. Although 
there is accumulating evidence suggesting that 
administering IV tPA in thrombectomy-eligible 
patients may be futile,32–34 there are also data sug-
gesting that it may be beneficial in patients with 
LVO.35 Further complicating the matter, IV tPA 
efficacy depends on thrombus location meaning 
that proximal thrombi are less likely to respond to 
thrombolysis, whereas tPA has a higher likelihood 
of inducing recanalization at more distally located 
thrombi.36,37 The best available evidence comes 
from a recent randomized trial conducted in 
China (DIRECT-MT), where EVT alone was 
non-inferior with regard to functional outcome 
(within a 20% margin of confidence) to EVT pre-
ceded by intravenous alteplase administered 
within 4.5 h after symptom onset.38 Future trials 
comparing thrombectomy with thrombolysis may 
need to include analyses of thrombus location. 
Randomized controlled trials comparing the safety 
and efficacy of thrombectomy with tPA versus 
thrombectomy alone are currently underway 
(SWIFT DIRECT, ClinicalTrials.gov, NCT 
03192332; MR CLEAN-NOIV, ISRCTN 
80619088). According to current guidelines, eligi-
ble patients with anterior circulation LVO should 
receive combined therapy but IV tPA should not 
delay thrombectomy.
Distal occlusions
The anatomical definition of an anterior circula-
tion LVO may be variable39 but in recent rand-
omized trials occlusions of the intracranial 
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internal carotid artery or the first segment of the 
middle cerebral artery were commonly classified 
as LVO.1,10,12 A major reason to withhold EVT in 
acute ischemic stroke patients are “too” distal 
occlusions, even in patients with substantial 
penumbra. According to data from large interna-
tional registries (for example the STAR, STOP 
Stroke or Intersect registries), this patient popula-
tion accounts for up to 30% of all patients with 
intracranial vessel occlusions.40 Data for distal 
occlusions, also named medium vessel occlusions 
(MeVOs, including the M2, M3 or M4 segments 
of the middle cerebral artery, the A1, A2 or A3 
segments of the anterior cerebral artery and the 
P1 or P2 segments of the posterior cerebral artery) 
are comparably sparse because randomized trials 
focused mainly on LVO. However, some patients 
(under 10%) with M2 occlusions were also 
enrolled in the afore-mentioned trials either due 
to protocol violations or because they were not 
explicitly excluded from the trial.1 In 95 patients 
with isolated M2 occlusions that were finally 
included in the HERMES meta-analysis (51 were 
treated with EVT), there was a trend towards pos-
itive treatment effect of EVT (OR 1.28 (95% con-
fidence interval (CI) 0.51–3.21).1 After including 
individual patient data from the PISTE and 
THRACE trials and revisiting the definition of 
M2 occlusions, the number of patients in a sec-
ond HERMES meta-analysis increased to 130 
(67 treated with EVT) leading to a OR in favor of 
EVT of 1.68 (95% CI 0.90–3.14).15 An analysis 
of these data by Menon et al.41 revealed a signifi-
cantly higher percentage of functionally inde-
pendent patients (mRS ⩽2) in the EVT group 
with an absolute difference of 18.5% (p = 0.04). 
Nonetheless, guidelines regarding the treatment 
of M2 occlusions were not changed by the 
American Stroke Association (ASA)42 and the 
European Stroke Organization (ESO) because 
the data were deemed insufficient to give an evi-
dence-based recommendation in favor or against 
EVT in M2 occlusions.43 The main objection was 
that selection bias could not be ruled out, because 
71 patients (54.62%) in the analysis were enrolled 
despite not being eligible under the primary inclu-
sion criteria. This means that a large proportion 
of patients were re-classified as M2 occlusions in 
retrospect even though they were misclassified as 
having an M1 occlusion at the time of enrollment. 
This naturally raises concerns about generating a 
disproportional sample of proximal and large M2 
occlusions, limiting the external validity of the 
data. Conclusively, a large survey among 600 
physicians in Europe found that ~40% would not 
pursue EVT in patients with M2 occlusions.44 
Even in relatively young patients (56 years old) in 
the early time window (3 h from symptom onset) 
with incapacitating deficits at presentation (global 
aphasia) and clear signs of salvageable penumbra 
only ~56% of the clinicians decided in favor of 
EVT even under assumed perfect conditions.44
The benefit of thrombectomy for more distal 
MCA occlusions, such as the M3 segments, or 
anterior cerebral artery occlusions is unclear 
despite a number of studies evaluating the out-
comes of thrombectomy in these patients. 
Although studies indicate that thrombectomy 
may be safe and effective in patients with distal 
anterior circulation LVO, evidence also suggests 
an increased risk profile with mechanical inter-
ventions, such as vessel perforation and vasos-
pasm.45–48 A recent multicenter study and 
literature review for isolated posterior cerebral 
artery occlusions comes to the conclusion that the 
procedure itself is technically feasible and safe but 
further studies are needed to investigate safety 
and long-term functional outcomes with poste-
rior circulation.49 This is especially important 
because the natural history of distal occlusions is 
on average more favorable than of proximal 
occlusions and therefore EVT should directly be 
compared with best medical management alone 
in a randomized trial. We conclude that patients 
with distal occlusions, and where the target occlu-
sion can be safely reached by EVT, should be 
treated with EVT in selected cases, where a clini-
cal benefit can be expected.
Milder strokes
When determining eligibility for thrombectomy, 
stroke severity should be assessed using the 
National Institutes of Health Stroke Scale 
(NIHSS),50 which objectively measures clinical 
deficits and may identify those at higher risk for 
complications. There was significant variability in 
the NIHSS thresholds used for inclusion in recent 
randomized controlled trials (RCTs) for thrombec-
tomy. The MR CLEAN trial had the lowest 
NIHSS threshold of 2, ESCAPE and EXTEND-IA 
set no specific NIHSS thresholds, but required 
the symptoms to be ‘disabling’, whereas other tri-
als had variable NIHSS thresholds, ranging from 
6 to 10.1 Because several trials independently 
validated an NIHSS threshold of 6 (SWIFT 
PRIME, REVASCAT and DEFUSE 3), an 
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NIHSS of >6 may serve as a working criterion of 
clinical severity when considering thrombectomy 
in anterior circulation stroke. Data for patients 
presenting with anterior circulation LVO and 
NIHSS <6 are sparse, with occasional worsening 
of neurological deficits.51,52 A large recent multi-
centre study including a meta- analysis of availa-
ble data suggested similar outcomes of EVT and 
best medical treatment in these patients and con-
cluded that clinical equipoise can further be 
resolved by a randomized clinical trial.53 Of note, 
the NIHSS carries its own set of limitations and 
often does not fully capture functional impair-
ment. Furthermore, even so-called “non-disa-
bling” strokes with low NIHSS can be devastating 
from a patient perspective: Mild to moderate dys-
arthria for example results in an NIHSS score of 
1 but will prevent teachers, lawyers and doctors 
from returning back to work. On the other hand, 
stroke centers may deem that the benefit gained 
from EVT in mild stroke does not outweigh the 
risks to the patient from performing the proce-
dure. Moreover, the likelihood of the mild stroke 
becoming a disabling stroke is less than for more 
severe strokes so that it is necessary to treat mild 
strokes on an individual basis taking into account 
all the risks but also what every individual patient 
can potentially gain from EVT for continuing his 
individual life. As a consequence, in milder 
strokes EVT should only be performed after con-
sideration of the potential risks and benefits.
Tandem occlusions
In the HERMES meta-analysis (122 of 1254 
occlusions) and in THRACE (24 of 196) tandem 
occlusions were included.54 In HERMES, there 
was a heterogeneity of treatment methods for the 
extracranial carotid occlusion (no revasculariza-
tion/angioplasty/stenting). A retrospective analysis 
of pooled data from 18 centers examined 395 
patients with tandem occlusions of the anterior 
circulation who underwent mechanical thrombec-
tomy [TITAN (Thrombectomy in Tandem 
Lesions)].55 Successful recanalization (mTICI 
grade 2b/3) was achieved in ~76% of patients and 
at 90 days ~52% showed a good functional out-
come, whereas ~14% had parenchymal hematoma 
and mortality was ~13%.56 Newer techniques of 
simultaneous thrombectomy and carotid stenosis 
treatment have emerged and could further increase 
the recanalization rates while reducing the time of 
the intervention.57 Based on this information a 
randomized trial by the TITAN collaboration is 
underway.58 Based on these preliminary data, we 
recommend to perform EVT in tandem occlu-
sions with intracranial LVO.
Pediatric strokes
In children with arterial ischemic stroke with 
LVO, after several small case series,59,60 the 
recently published Save ChildS Study provided 
multicenter evidence that justifies mechanical 
thrombectomy as a feasible treatment option.61 
As LVO is a rare event in the pediatric population 
and not suitable for randomized evaluation, Save 
ChildS attempted to capture real world treatment 
regimens in a large retrospective multicenter 
study design. All pediatric patients (<18 years) 
with ischemic stroke who underwent endovascu-
lar recanalization were screened across 42 stroke 
centers in Europe and the United States. 
Thrombectomy performed in 27 centers revealed 
that most of the children had favorable neurologi-
cal outcomes and the rate of recanalization and 
adverse events was comparable to randomized 
controlled trials in adults.61 Furthermore, a sec-
ondary analysis of this study investigating device 
selection in different ages and etiologies showed 
that neurological outcomes are generally good 
regardless of any specific device selection and 
suggests that it is important to offer thrombec-
tomy in eligible children regardless of technique 
or device selection.62 Data for thrombectomy in 
children in the extended time window are limited 
to case reports.63–67 However, a secondary analy-
sis of the Save ChildS study has recently shown 
that thrombectomy in an extended time window 
of up to 24 h after onset of symptoms was safe and 
neurological outcomes were generally good, if 
patients were selected by a mismatch between 
clinical deficit and infarct.68 The 2019 AHA 
guidelines were written before this evidence 
became available.69 We therefore recommend to 
perform EVT in pediatric patients with LVO even 
in the extended time window beyond 6 h after 
symptom onset. However, caution should be 
especially applied if an underlying arteriopathy is 
suspected.
Conclusions
In conclusion, we recommend to perform EVT 
patients with vertebrobasilar occlusions and tan-
dem occlusions. In the extended time window 
EVT should be performed if there is relevant sal-
vageable brain tissue. Moreover, elderly patients, 
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Table 1. Indications for EVT. 
Indication AHA/ASA guidelines ESO/ESMINT guidelines Other evidence + recommendation of 
the authors
Time from symptom onset In selected patients with AIS 
within 6–16 h of last known 
normal who have LVO in the 
anterior circulation and meet 
other DAWN or DEFUSE 3 
eligibility criteria, mechanical 
thrombectomy is recommended.
Level of evidence A
In selected patients with AIS 
within 16–24 h of last known 
normal who have LVO in the 
anterior circulation and meet 
other DAWN eligibility criteria, 
mechanical thrombectomy is 
reasonable.
Level of evidence B-R
In adults with anterior circulation 
large vessel occlusion-related 
acute ischemic stroke presenting 
between 6 and 24 h from time 
last known well and fulfilling the 
selection criteria of DEFUSE-3 or 
DAWN, ESO/ESMINT recommends 
mechanical thrombectomy plus 
best medical management over 
best medical management alone to 
improve functional outcome.
Quality of evidence: 
Moderate ⊕⊕⊕; strength of 
recommendation: Strong ↑↑
EVT should be performed whenever 
there is relevant salvageable brain 
tissue on advanced imaging within
Extent of infarction 
(ASPECTS)
Pre-existing deficits
Milder strokes (NIHSS <6)
Although its benefits are 
uncertain, the use of mechanical 
thrombectomy with stent 
retrievers may be reasonable 
for patients with AIS in whom 
treatment can be initiated (groin 
puncture) within 6 h of symptom 
onset and who have prestroke 
mRS score >1, ASPECTS <6, or 
NIHSS score <6, and causative 
occlusion of the internal carotid 
artery (ICA) or proximal MCA 
(M1).
Level B-R
ESO/ESMINT recommends that 
patients with anterior circulation 
stroke with extensive infarct core 
(e.g. ASPECTS 70 mL or >100 mL) 
should be included in randomized 
controlled trials comparing 
mechanical thrombectomy plus 
best medical management with 
best medical management alone.
Quality of evidence: Very low ⊕;
strength of recommendation: –
ESO/ESMINT recommends that 
patients with low stroke severity 
(NIHSS score 0–5) and large 
vessel occlusion-related acute 
ischemic stroke within 24 h 
from time last known well be 
included in randomized controlled 
trials comparing mechanical 
thrombectomy plus best medical 
management versus best medical 
management alone.
Quality of evidence: Very low ⊕;
strength of recommendation: –
HERMES meta-analysis found better 
clinical outcomes at 90 days in patients 
with ASPECTS <615
Retrospective studies found increased 
rates of favorable outcomes and less 
edema formation in patients with 
ASPECTS <616,18
We conclude that patients with 
ASPECTS 4–6 should be treated with 
EVT and even patients with ASPECTS 
lower than 3 might benefit in selected 
cases.
We conclude, that pre-existing deficits 
should not lead to exclusion of these 
patients from EVT.
Meta-analysis found similar outcomes 
of EVT and best medical treatment for 
patients with NIHSS <653
We conclude, that in milder strokes 
EVT should only be performed after 
careful consideration of the potential 
risks and benefits.
EVT and intravenous 
thrombolysis
Patients eligible for IV alteplase 
should receive IV alteplase even 
if mechanical thrombectomy is 
being considered.
Level A
In patients with large vessel 
occlusion-related ischemic stroke 
eligible for both treatments, ESO/
ESMINT recommends intravenous 
thrombolysis plus mechanical 
thrombectomy over mechanical 
thrombectomy alone. Both 
treatments should be performed 
as early as possible after hospital 
arrival. Mechanical thrombectomy 
should not prevent the initiation 
of intravenous thrombolysis, 
and intravenous thrombolysis 
should not delay mechanical 
thrombectomy.
Quality of evidence: Very low ⊕;
strength of recommendation: 
Strong ↑↑
Randomized trial found EVT alone 
non-inferior with regard to functional 
outcome (within a 20% margin of 
confidence) to EVT preceded by 
intravenous alteplase administered 
within 4.5 h after symptom onset38
(Continued)
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Although the benefits are 
uncertain, the use of mechanical 
thrombectomy with stent 
retrievers may be reasonable for 
carefully selected patients with 
AIS in whom treatment can be 
initiated (groin puncture) within 
6 h of symptom onset and who 
have causative occlusion of the 
MCA segment 2 (M2) or MCA 
segment 3 (M3) portion of the 
MCAs.
Level B-R
Although the benefits are 
uncertain, the use of mechanical 
thrombectomy with stent 
retrievers may be reasonable 
for carefully selected patients 
with AIS in whom treatment can 
be initiated (groin puncture) 
within 6 h of symptom onset and 
who have causative occlusion of 
the anterior cerebral arteries, 
vertebral arteries, basilar artery, 
or posterior cerebral arteries.
Level C-LD
Expert opinion on mechanical 
thrombectomy for M2 occlusion:
There is a consensus among the 
guideline group (11/11 votes) that 
patients with M2 occlusion fulfilled 
the inclusion criteria in most 
randomized trials and therefore 
mechanical thrombectomy is 
reasonable in this situation.
Expert opinion on mechanical 
thrombectomy for basilar artery 
occlusion:
There is a consensus among the 
panel (11/11 votes) that in analogy 
to anterior circulation large vessel 
occlusion and with regard to the 
grim natural course of basilar 
artery occlusions, the therapeutic 
approach with intravenous 
thrombolysis plus mechanical 
thrombectomy should strongly be 
considered.
We conclude, that patients with distal 
occlusions and where the target 
occlusion can be reached safely, 
should be treated with EVT in selected 
cases, where a clinical benefit can be 
expected.
– randomized trial found no difference 
in favorable outcomes of patients 
receiving EVT versus medical therapy 
alone but may be confounded by loss 
of equipoise over the course of the 
trial24
Nonetheless, we recommend 
to perform EVT in patients with 
vertebrobasilar artery occlusions.
Tandem occlusions Treatment of tandem 
occlusions (both extracranial 
and intracranial occlusions) 
when performing mechanical 
thrombectomy may be 
reasonable.
Level B-R
No recommendation can be 
provided regarding which 
treatment modality should be 
favored in patients with large 
vessel occlusion-related acute 
ischemic stroke and associated 
extracranial carotid artery stenosis 
or occlusion. ESO/ESMINT 
recommends the inclusion of such 
patients in dedicated randomized 
controlled trials.
Quality of evidence: Very low ⊕; 
strength of recommendation: –
Retrospective study found good rates 
of successful recanalization (76%) and 
good functional outcome (52%) but 
also parenchymal hematoma in 14% 
and death in 13%55
We recommend to perform EVT in 
tandem occlusions with intracranial 
LVO.
Pediatric strokes In the absence of pediatric 
clinical trial data to guide 
treatment decisions, hyperacute 
therapies for childhood AIS 
remain controversial.69
– Retrospective Save ChildS Study 
found good clinical outcomes and 
low complication rates regardless of 
device selection61,62
We recommend to perform EVT in 
pediatric patients with LVO but caution 
should be applied if an underlying 
arteriopathy is suspected.
The AHA/ASA guideline information is from the 2018 guideline of the American Heart Association/Stroke Association (AHA/ASA) which contains the 
following general sentence for EVT: “Patients should receive mechanical thrombectomy with a stent retriever if they meet all the following criteria: 
(1) prestroke mRS score of 0–1; (2) causative occlusion of the internal carotid artery or MCA segment 1 (M1); (3) age ⩾18 years; (4) NIHSS score of 
⩾6; (5) ASPECTS of ⩾6; and (6) treatment can be initiated (groin puncture) within 6 h of symptom onset.”70
The level of evidence in the AHA/ASA guidelines is categorized as follows:
Level A: high-quality evidence from more than one randomized controlled trial (RCT); meta-analyses from the RCTs; one or more RCTs corroborated 
by high-quality registry studies.
Level B-R (randomized): moderate-quality evidence from one or more RCTs; meta-analyses from the RCTs.
Level C-LD (limited data): randomized or non-randomized observational or registry studies with limitations of design or execution; meta-analyses 
of such studies; physiological or mechanistic studies in human subjects.
The ESO/ESMINT guideline information is from the 2019 European Stroke Organisation (ESO) – European Society for Minimally Invasive 
Neurological Therapy (ESMINT) guidelines on mechanical thrombectomy in acute ischaemic stroke endorsed by Stroke Alliance for Europe (SAFE). 
The level of evidence and quality of data is from the ESO/ESMINT guidelines.70
Table 1. (Continued)
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patients with distal occlusions or with extensive 
signs of infarction and patients with pre-existing 
deficits should not be excluded from thrombec-
tomy. Based on the current evidence intravenous 
thrombolysis should be administered as an 
adjunct to EVT. Pediatric patients with large ves-
sel occlusions should be treated with EVT but 
caution should be applied when underlying arte-
riopathies are suspected.
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